Annals of Neurology · 2020 · 48 citations · 44 references
MedicineNeurologyPathologyDementiaNeuropathologyNeuropsychiatryAlzheimer DiseaseCognitive ImpairmentFrontotemporal DementiaNeurodegenerative DiseasesNeurodegenerative DisordersNeuropathology Of DementiaAlzheimer's Disease DiagnosisDementia Comorbidity PatternsFrontotemporal Dementia DiagnosisNeuropsychiatric ManifestationsNeuropsychiatric Symptoms Of DementiaSymptom InterpretationTar Dna-binding Protein 43 Pathology
OBJECTIVE: The pathology of frontotemporal dementia, termed frontotemporal lobar degeneration (FTLD), is characterized by distinct molecular classes of aggregated proteins, the most common being TAR DNA-binding protein-43 (TDP-43), tau, and fused in sarcoma (FUS). With a few exceptions, it is currently not possible to predict the underlying pathology based on the clinical syndrome. In this study, we set out to investigate the relationship between pathological and clinical presentation at single symptom level, including neuropsychiatric features. METHODS: The presence or absence of symptoms from the current clinical guidelines, together with neuropsychiatric features, such as hallucinations and delusions, were scored and compared across pathological groups in a cohort of 150 brain donors. RESULTS: Our cohort consisted of 68.6% FTLD donors (35.3% TDP-43, 28% tau, and 5.3% FUS) and 31.3% non-FTLD donors with a clinical diagnosis of frontotemporal dementia and a different pathological substrate, such as Alzheimer's disease (23%). The presence of hyperorality points to FTLD rather than non-FTLD pathology (p < 0.001). Within the FTLD group, hallucinations in the initial years of the disease were related to TDP-43 pathology (p = 0.02), including but not limited to chromosome 9 open reading frame 72 (C9orf72) repeat expansion carriers. The presence of perseverative or compulsive behavior was more common in the TDP-B and TDP-C histotypes (p = 0.002). INTERPRETATION: Our findings indicate that neuropsychiatric features are common in FTLD and form an important indicator of underlying pathology. In order to allow better inclusion of patients in targeted molecular trials, the routine evaluation of patients with frontotemporal dementia should include the presence and nature of neuropsychiatric symptoms. ANN NEUROL 2020;87:950-961.
44
Staging of brain pathology related to sporadic Parkinson’s disease
Heiko Braak, Kelly Del Tredici, Udo Rüb et al. · Neurobiology of Aging · 2002 · 10.8K citations
Medicine, Neurology, Neuroscience +13
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Katya Rascovsky, John R. Hodges, David S. Knopman et al. · Brain · 2011 · 5.3K citations · Full text
Medicine, Neurology, Psychiatry +17
Classification of primary progressive aphasia and its variants
Maria‐Luisa Gorno‐Tempini, Argye E. Hillis, Andrew Kertesz et al. · Neurology · 2011 · 5.1K citations · Full text
Health Professions, Neurology, Speech-language Pathology +17
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Dietmar Rudolf Thal, Udo Rüb, M Orantes et al. · Neurology · 2002 · 3.5K citations